Voyageur Pharmaceuticals Appoints Financial Executive Virginia Alling to Board to Accelerate U.S. Market Expansion

Voyageur Pharmaceuticals Ltd. has appointed Virginia Alling as an independent director, subject to regulatory approval, marking another strategic addition to the company's board as it prepares for accelerated U.S. market expansion. This appointment follows recent board enhancements with Wall Street veterans Jeffrey J. Kraws and Christopher A. Van Buren, collectively positioning the Canadian pharmaceutical developer for improved U.S. capital market access and strategic growth initiatives.

Alling brings over three decades of experience in corporate banking, capital markets, and strategic advisory services for both privately held and publicly traded companies. As Senior Vice President & Managing Director at PNC Bank in East Brunswick, New Jersey, she manages a multi-billion-dollar portfolio of corporate clients across New Jersey and New York, with expertise spanning mergers and acquisitions, initial public offerings, employee stock ownership plans, leveraged finance, and revenue optimization strategies. Her background includes guiding private equity-backed and multigenerational family-owned businesses through complex capital structure solutions, succession planning, and comprehensive risk management frameworks.

Brent Willis, Voyageur's CEO, emphasized the strategic importance of Alling's appointment, noting her proven track record in executing U.S. public offerings, revenue optimization, and cross-border financing complements the company's recent board additions. Willis stated that Alling's deep experience in M&A and capital markets will be instrumental in unlocking institutional U.S. investment, streamlining the company's U.S. market entry strategy, and ensuring robust governance as Voyageur scales its innovative barium and iodine pipeline for North American healthcare providers.

The collective expertise of Alling, Kraws, and Van Buren underscores Voyageur's commitment to assembling a high-caliber board with demonstrated Wall Street acumen to facilitate the company's U.S. market expansion objectives. Their combined experience in revenue generation, IPO execution, and regulatory compliance is expected to support Voyageur's commercialization efforts, including pursuing FDA approvals for its barium contrast products and scaling operations at its Oklahoma iodine facilities. Voyageur's strategic focus involves vertically integrating the barium and iodine contrast markets, aiming to become a key player by producing its own pharmaceutical-grade materials while controlling all primary input costs from raw material sourcing to final production.

Voyageur's business model centers on generating sales through partnerships with established third-party GMP pharmaceutical manufacturers in Canada, ensuring product validation by regulatory agencies worldwide. The company owns a 100% interest in the Frances Creek barium sulphate project, which features rare high-grade mineral resources suitable for pharmaceutical applications. Voyageur believes its natural barium products will replace current synthetic alternatives in the pharmaceutical marketplace, offering higher quality imaging products for medical diagnostics. Additional information about the company's operations and forward-looking statements can be found in its disclosure documents on the SEDAR+ website at https://www.sedarplus.ca.